---
figid: PMC8999051__ijms-23-03559-g003
pmcid: PMC8999051
image_filename: ijms-23-03559-g003.jpg
figure_link: /pmc/articles/PMC8999051/figure/ijms-23-03559-f003/
number: Figure 3
figure_title: ''
caption: Tisotumab Vedotin molecular pathway of action.
article_title: 'Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?.'
citation: Margherita Turinetto, et al. Int J Mol Sci. 2022 Apr;23(7):3559.
year: '2022'

doi: 10.3390/ijms23073559
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- cervical cancer
- immunotherapy
- immune checkpoint inhibitors
- therapeutic vaccines
- TILs
- tisotumab vedotin
- human papillomavirus

---
